



ChessonLabs

FOR IMMEDIATE RELEASE

Chesson Labs Applies CE Mark to Its Nail Fungus Product in Europe

DURHAM, NC, USA. January 26, 2011 ----- Chesson Laboratory Associates, Inc., an innovator of polymer-based healthcare products, announces CE marking of LIQUICURE[®], a topical product to manage onychomycosis (nail fungus). The CE Mark as a Class 1 Medical Device allows LIQUICURE to be marketed throughout Europe.

A multi-center clinical trial, completed in 2010, demonstrated the safety and effectiveness of LIQUICURE on patients with toenail fungus. The treatment regimen in the clinical trial was a topical application five times a week to the infected nail(s), for six months. The primary efficacy endpoint was clearance of fungal nail infection, defined by negative dermatophyte culture. A single, nationally-accredited core microbiology lab, blinded to all other aspects of the study, was used to assess results. The clinical study data, which showed over 60% efficacy and nail visual improvement rates, are slated to be published in the Journal of Drugs in Dermatology (JDD).

Chesson Labs successfully completed all the requirements necessary to complete its declaration of conformity, allowing the Company to apply the CE mark. "We are happy to have completed the requirements that allow Chesson Labs to enter the European marketplace" said Scott Neuville, President and CEO. "The timing of this, so close to the agreement we reached in India, demonstrates our commitment to international expansion."

The Company is also seeking FDA clearance to market the product in the United States.

ABOUT CHESSON LABS

Chesson Laboratory Associates, Inc. is a privately funded healthcare products company founded in 2006. Chesson Labs' proprietary products in development for use by healthcare professionals and consumers are based on innovative patented and patent-pending polymer-based technology. The mission of Chesson Labs is to improve global healthcare by becoming a market leader in the development and delivery of innovative polymer-based medical products.

Chesson Labs is headquartered in the University Tower in Durham, NC, with a research and development facility less than 10 miles away. For more information, visit www.chessonlabs.com.

CHESSON LABS CONTACTS:

Scott E. Neuville, President & CEO

919.419.4900 (office)